This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TPJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.

Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment

Support
This educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.

Disclosure information is available at the beginning of the video presentation.

Scott Kopetz, MD, PhD, FACP - Therapeuti...